Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major growing global disease. This symposium will address the variations in prevalence, diagnostic methods, and therapeutic options as it relates to MASLD, in different parts of the wor

Part 1: Portal Hypertension

With the projected deficit in hepatology providers identified by the Hepatology Workforce Study APPs are uniquely positioned to bridge the gap in access to hepatology care. This program will identify specific areas where APPs have an evolving impact.

This session covers the recent discoveries from studies in experimental cholestasis models and results of clinical trials targeting the gut-liver axis. Several investigations in patients with inflammatory cholestatic disease, i.e., PSC or biliary atresia,

The recent advances in the cellular and geospatial immuno-genomic heterogeneity of cholangiocarcinoma may impact the future therapeutic approaches for this malignancy. Attendees will review the current and emerging strategies to manage the disease (i.e.,

Part 2: Pushing the envelope in liver transplantation

Part 2: Innovations in pediatric and young adult MASLD

Part 1: MASLD in pediatrics and young adults

Part 1: Epidemic of Severe Acute Hepatitis in Children: Epidemiology, Breakthroughs, and Future Response

Five 15-minute talks on the identified unmet needs in the management of PBC and PSC will be presented to attendees, followed by a multidisciplinary 15-minute Q&A discussion. Each speaker will review the current data on the topic and conclude with eith